Q-omics provides the consensus-scored SIGLEC15 profile across patient tissues and cancer cell-line models. SIGLEC15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SIGLEC15 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SIGLEC15 RNA expression shows 15,168 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, COAD, and THYM as cancer lineages where SIGLEC15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGLEC15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGLEC15 survival associations across molecular data types. SIGLEC15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGLEC15 RNA expression–survival associations across cancer types. High SIGLEC15 expression shows unfavorable associations in SARC and LGG, but favorable associations in BLCA, UCEC, DLBC and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SIGLEC15 RNA expression.
This table summarizes SIGLEC15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SIGLEC15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGLEC15 shows higher tumor expression in COAD, HNSC, THCA, KICH, UCEC and STAD. The COAD box plot shows higher SIGLEC15 RNA expression in tumor versus normal tissue (log2 FC = +0.875, t-test p < 0.001).
This table shows molecular features associated with SIGLEC15 in patient tissues and cancer cell lines. In patient samples, SIGLEC15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SIGLEC15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
